Amyloid-β1-15/16 as a marker for γ-secretase inhibition in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 31, Issue 2, 2012, Pages 335-341

  Portelius, Erik ^a   Zetterberg, Henrik ^a   Dean, Robert A ^b   Marcil, Alexandre ^c   Bourgeois, Philippe ^c   Nutu, Magdalena ^a   Andreasson, Ulf ^a   Siemers, Eric ^b   Mawuenyega, Kwasi G ^d   Sigurdson, Wendy C ^d   May, Patrick C ^b   Paul, Steven M ^b   Holtzman, David M ^d   Blennow, Kaj ^a   Bateman, Randall J ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid ; secretase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-15/16]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; PLACEBO; SEMAGACESTAT; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84865518001     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120508     Document Type: Article

References (19)

1. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
2. Caselli RJ, Beach TG, Yaari R, Reiman EM (2006) Alzheimer's disease a century later. J Clin Psychiatry 67, 1784-1800. (Pubitemid 44955162)
3. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 120, 185-193.
4. Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS (2007) The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320, 552-558. (Pubitemid 46147933)
5. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A (2007) 1-(3-,4-Dichloro-2-fluoro[1,1-biphenyl]-4-yl)- cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323, 822-830.
6. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
7. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R,Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32, 1090-1098.
8. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12. (Pubitemid 36423348)
9. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K,Westman-Brinkmalm A (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6, 4433-4439. (Pubitemid 350158518)
10. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 61, 1965-1968. (Pubitemid 23317227)
11. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gammasecretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038.
12. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66, 48-54.
13. Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ (2010) Acute gamma-secretase inhibition of nonhuman primateCNSshifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 30, 6743-6750.
14. Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2, 7.
15. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K (2010) Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 21, 1005-1012.
16. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, HoltzmanDM(2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12, 856-861. (Pubitemid 44050079)
17. Bielefeld-Sevigny M (2009) AlphaLISA immunoassay platform-the "no-wash" high-throughput alternative to ELISA. Assay Drug Dev Technol 7, 90-92.
18. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K (2011) Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: A cross-sectional study. Neurology 76, 366-372.
19. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30, 317-325. (Pubitemid 350307310)